Movement Alert｜Keymed Biosciences Rises 5.08% in Regular Trading, Core Product Included in New National Essential Drug List with Multiple Brokerages Maintaining Buy Ratings

Market Focus07-15

On July 15, Keymed Biosciences (02162.HK) rose 5.08% in regular trading, trading at 85.45 HKD/share, with turnover of approximately 74.15 million HKD.

The rally was driven by dual catalysts: the company's core product was selected for inclusion in the newly released National Essential Drug List, and multiple brokerages including Huayuan Securities, Guotai Haitong Securities, and Guosen Securities issued research reports maintaining or initiating buy ratings. Bocom International noted that the new list added 116 varieties, with essential drugs accounting for 71% of total drug usage across public medical institutions nationwide.

Brokerages highlighted the convergence of commercialization ramp-up and BD revenue realization. Gilead's acquisition of Ouro Medicines has delivered a $257 million upfront payment, with significant milestone payment upside remaining. Guotai Haitong initiated coverage with a target price of 138.91 HKD, projecting 2026 revenue of 3.09 billion yuan. The broader biotech sector rallied in tandem, with SKB Bio up 9.8% and Innovent Bio up 5.94%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177680001?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177680001","market":"us","top_or_hot":-1,"title":"Movement Alert｜Keymed Biosciences Rises 5.08% in Regular Trading, Core Product Included in New National Essential Drug List with Multiple Brokerages Maintaining Buy Ratings","media":"Market Focus","content":"<p><p>On July 15, Keymed Biosciences (02162.HK) rose 5.08% in regular trading, trading at 85.45 HKD/share, with turnover of approximately 74.15 million HKD.</p><p>The rally was driven by dual catalysts: the company's core product was selected for inclusion in the newly released National Essential Drug List, and multiple brokerages including Huayuan Securities, Guotai Haitong Securities, and Guosen Securities issued research reports maintaining or initiating buy ratings. Bocom International noted that the new list added 116 varieties, with essential drugs accounting for 71% of total drug usage across public medical institutions nationwide.</p><p>Brokerages highlighted the convergence of commercialization ramp-up and BD revenue realization. Gilead's acquisition of Ouro Medicines has delivered a $257 million upfront payment, with significant milestone payment upside remaining. Guotai Haitong initiated coverage with a target price of 138.91 HKD, projecting 2026 revenue of 3.09 billion yuan. The broader biotech sector rallied in tandem, with SKB Bio up 9.8% and Innovent Bio up 5.94%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Keymed Biosciences Rises 5.08% in Regular Trading, Core Product Included in New National Essential Drug List with Multiple Brokerages Maintaining Buy Ratings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Keymed Biosciences Rises 5.08% in Regular Trading, Core Product Included in New National Essential Drug List with Multiple Brokerages Maintaining Buy Ratings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Keymed Biosciences (02162.HK) rose 5.08% in regular trading, trading at 85.45 HKD/share, with turnover of approximately 74.15 million HKD.</p><p>The rally was driven by dual catalysts: the company's core product was selected for inclusion in the newly released National Essential Drug List, and multiple brokerages including Huayuan Securities, Guotai Haitong Securities, and Guosen Securities issued research reports maintaining or initiating buy ratings. Bocom International noted that the new list added 116 varieties, with essential drugs accounting for 71% of total drug usage across public medical institutions nationwide.</p><p>Brokerages highlighted the convergence of commercialization ramp-up and BD revenue realization. Gilead's acquisition of Ouro Medicines has delivered a $257 million upfront payment, with significant milestone payment upside remaining. Guotai Haitong initiated coverage with a target price of 138.91 HKD, projecting 2026 revenue of 3.09 billion yuan. The broader biotech sector rallied in tandem, with SKB Bio up 9.8% and Innovent Bio up 5.94%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1177680001","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177680001","pubTimestamp":1784080219,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Keymed Biosciences (02162.HK) rose 5.08% in regular trading, trading at 85.45 HKD/share, with turnover of approximately 74.15 million HKD.The rally was driven by dual catalysts: the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"走势预警|凯域生科常规交易大涨5.08%，核心产品纳入新国家基本药物目录，多家券商维持买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"On July 15, Keymed Biosciences (02162.HK) rose 5.08% in regular trading, trading at 85.45 HKD/share, with turnover of approximately 74.15 million HKD.The rally was driven by dual catalysts: the company's core product was selected for inclusion in the newly released National Essential Drug List, and multiple brokerages including Huayuan Securities, Guotai Haitong Securities, and Guosen Securities issued research reports maintaining or initiating buy ratings. Bocom International noted that the new list added 116 varieties, with essential drugs accounting for 71% of total drug usage across public medical institutions nationwide.Brokerages highlighted the convergence of commercialization ramp-up and BD revenue realization. Gilead's acquisition of Ouro Medicines has delivered a $257 million upfront payment, with significant milestone payment upside remaining. Guotai Haitong initiated coverage with a target price of 138.91 HKD, projecting 2026 revenue of 3.09 billion yuan. The broader biotech sector rallied in tandem, with SKB Bio up 9.8% and Innovent Bio up 5.94%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177680001","isCrawlerRequest":true}